DVAX: Dynavax Technologies Company Aggregate Debts

Symbol and logo of brand Dynavax Technologies (DVAX)

The market trend for Dynavax Technologies (DVAX) shares reflects the dynamics of a specific debt, which currently stands at 0.28. The business is expanding its presence in the hepatitis B protection sector by attracting new corporate clients. Revenues are based on the sale of the high-margin CpG 1018 adjuvant and the commercialization of its flagship vaccine. Its status as a recognized expert in immunization ensures the company receives unconditional recognition from the medical community.

DVAX: Dynavax Technologies Corp Company Debts 07/04/2022 - 02/21/2026

Dynavax Pharma (DVAX) - metric breakdowns and financial figures

- share price and consensus valuation forecast:
Price Performance Chart Dynavax Technologies Corp|DVAX - Analyst Consensus Forecast
- market capitalization information:
Market Capitalization Dynavax Corp|DVAX - Total Company Value
- balance sheet equity data:
Accounting Value of a Share Dynavax|DVAX - Company Book Value|Market Cap to Net Assets Ratio dynavax.com|DVAX - Company Total Assets
- issuer credit burden and liquidity indicators:
Total Debt to Capital Dynavax Technologies|DVAX - Long-Term Debt to Equity Ratio|Ratio of Short-Term Indebtedness to Capital Dynavax Technologies|DVAX - Company Debts|Debt to Book Capitalization Ratio Dynavax Corp|DVAX - Company Long-Term Debts|Short-Term Debt Volume Dynavax
Fundamental company analysis:Dynavax DVAX
Signature product of Dynavax Pharma

Dynavax Technologies (DVAX) maintains a high dependency on a single drug, necessitating significant R&D investments to diversify its portfolio. Total debt measures the aggregate volume of credit obligations, determining financial stability and the cost of capital. It is critical for investors to distinguish between planned growth financing and a critical debt burden. Analyzing the organization's debt profile allows for the exclusion of random fluctuations and an assessment of the predictability of loan management. A stable trajectory confirms the business's solvency.

Competing companies

ARWR (Arrowhead Corp) - Aggregate Debt Obligations|Company Aggregate Debts MIRM (Mirum Pharmaceuticals)|Company Aggregate Debts arbutusbio.com ABUS|IVA - Company Debts|Aggregate Debt Obligations GYRE (Gyre Therapeutics Inc)|Assembly Biosciences Inc (ASMB) - Company Debts|Company Total Debt Galectin Therapeutics Inc.|GNFT (Genfit SA) - Company Aggregate Debts|Company Aggregate Debts DURECT Corp.|Company Total Debt ALGS (Aligos Therapeutics)|BIVI (biovieinc.com) - Aggregate Debt Obligations|Company Debts Galmed Pharmaceuticals Ltd. GLMD|ENDRA Corp - Company Debts|Hepion Pharma - Company Aggregate Debts